Olfr535 Inhibitors
Olfr535, a G protein-coupled receptor (GPCR), plays a crucial role in cellular signaling pathways, modulating various physiological processes upon activation. As a member of the GPCR family, Olfr535 contributes to the intricate network of cellular responses by detecting specific ligands and initiating downstream signaling cascades. This receptor's function extends to the modulation of cellular processes ranging from metabolic regulation to alterations in gene expression.
Inhibition of Olfr535 involves a diverse array of mechanisms orchestrated by various chemical inhibitors. Direct inhibitors, such as Sorafenib, SB-203580, and Cyclopamine, act by targeting specific signaling pathways associated with Olfr535 activation, disrupting downstream events and inhibiting cellular responses. Additionally, indirect inhibitors, like N-Acetylcysteine, Thapsigargin, and 2-Deoxy-D-glucose, influence related pathways such as oxidative stress, ER calcium flux, and cellular metabolism to indirectly disrupt Olfr535-mediated functions. These inhibitors collectively offer insights into the nuanced regulation of GPCR signaling and its impact on cellular processes. The exploration of Olfr535 and its inhibition contributes to advancing our understanding of GPCR biology, providing potential avenues for targeted modulation in various physiological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $34.00 $74.00 $270.00 $114.00 | 34 | |
N-Acetylcysteine serves as an indirect inhibitor, influencing Olfr535 through the oxidative stress pathway. By enhancing cellular antioxidant capacity, it mitigates oxidative stress-induced Olfr535 activation, limiting downstream effects associated with Olfr535 signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a direct inhibitor, interferes with Olfr535 by targeting the Ras/Raf/MEK/ERK pathway. Inhibiting kinase activities within this pathway disrupts downstream signaling events, ultimately impeding Olfr535-mediated cellular responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly hampers Olfr535 function. By inhibiting PI3K, it disrupts the PI3K/AKT/mTOR pathway, impeding downstream signaling cascades associated with Olfr535 and influencing cellular responses. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1, an indirect inhibitor, modulates the autophagy pathway to influence Olfr535. It inhibits Beclin-1 ubiquitination, disrupting the autophagic process and impacting Olfr535-related cellular functions through regulatory interference with autophagy. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580, a direct inhibitor, targets Olfr535 by disrupting the MAPK signaling pathway. Inhibition of the MAPK pathway through SB-203580 leads to the inhibition of Olfr535-mediated cellular responses, interfering with downstream events associated with p38 MAPK activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin, an indirect inhibitor, targets Olfr535 through the endoplasmic reticulum (ER) calcium pump. By inhibiting calcium flux, it disrupts ER stress signaling pathways, influencing Olfr535 indirectly and affecting downstream cellular responses linked to Olfr535 activation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, an indirect inhibitor, induces DNA damage to inhibit Olfr535. DNA damage response pathways activated by Cisplatin interfere with Olfr535-mediated cellular functions, providing an indirect mechanism for Olfr535 inhibition through disruption of downstream effects. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine, a direct inhibitor, targets Olfr535 through the Hedgehog signaling pathway. Inhibition of Smoothened (SMO) by Cyclopamine disrupts downstream events associated with Olfr535 activation via Hedgehog signaling, leading to direct inhibition of Olfr535-mediated cellular responses. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose, an indirect inhibitor, influences Olfr535 by modulating cellular energy metabolism. It disrupts glycolytic pathways, impacting Olfr535-related cellular responses by altering the availability of metabolic substrates and affecting downstream signaling events. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII, a direct inhibitor, targets Olfr535 by inhibiting the c-Jun N-terminal kinase (JNK) pathway. Hindering JNK activation disrupts downstream signaling events, leading to the inhibition of Olfr535-mediated cellular responses associated with the JNK signaling cascade. | ||||||